Teva Hits Pause On Business Development, Even As Some Deals Stumble

Teva CEO Erez Vigodman said the company will step away from business development for the “foreseeable future” while it digests the acquisition of Allergan’s generic drug business.

Teva Pharmaceutical Industries Ltd. CEO Erez Vigodman said the company will focus on organic growth and step away from business development for the “foreseeable future” as it digests the $40.5bn acquisition of Allergan PLC.

“A significant amount of capital has been deployed over the last 12 months to acquire assets and partner with other...